Summary of Study ST000526
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000387. The data can be accessed directly via it's Project DOI: 10.21228/M81G7P This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000526 |
Study Title | Effects of Curcumin Supplementation on the Ceramides Concentration of Older Adults: Relation to Vascular Function (part 3) |
Study Summary | Perform ceramides concentrations metabolite analysis related to nitric oxide biology, oxidative stress and inflammation in plasma before and after 12 weeks of oral curcumin (2000 mg/d) or placebo (double-blind, randomized) in men and women aged 45-79 years who are free from clinical cardiovascular disease. |
Institute | Mayo Clinic |
Last Name | Seals |
First Name | Douglas |
Address | Department of Integrative Physiology University of Colorado Boulder, CO 80309 |
seals@colorado.edu | |
Phone | 303-492-5305 |
Submit Date | 2016-12-14 |
Analysis Type Detail | LC-MS |
Release Date | 2018-12-11 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000387 |
Project DOI: | doi: 10.21228/M81G7P |
Project Title: | Mayo Metabolomics Pilot and Feasibility Award: Effects of Curcumin Supplementation on the Plasma Metabolome of Older Adults: Relation to Vascular Function |
Project Summary: | Age is the major risk factor for cardiovascular diseases (CVD). Two key contributors to the increased risk of CVD in middle-aged and older (MA/O) adults are stiffening of the large elastic arteries and the development of vascular endothelial dysfunction, indicated by impaired nitric oxide (NO)-induced endothelium-dependent dilation (EDD). The mechanisms by which aging causes arterial dysfunction are incompletely understood, but involve reductions in NO bioavailability associated with the development of oxidative stress and inflammation. Thus, establishing novel strategies to reduce arterial stiffness and increase vascular endothelial function in MA/O adults by increasing NO bioavailability and reducing oxidative stress and inflammation are a high biomedical research priority. Curcumin is a naturally occurring phenol found in the Indian spice turmeric that improves physiological function in animal models of age-related diseases and is a promising nutraceutical for intervention for promoting healthy aging. Our preclinical results indicate that chow supplemented with curcumin reduces aortic pulse wave velocity (PWV), the most common and clinically important measure of large elastic artery stiffness, restores NO-mediated EDD and reduces arterial oxidative stress and inflammation in old C57/BL6 mice. Preliminary data from our recently funded NIH R21 pilot grant indicate that curcumin supplementation improves vascular function in humans. It is possible that changes in the circulating (plasma) metabolome with oral curcumin supplementation will provide insight into novel metabolic mechanisms by which curcumin may improve vascular function. The goal of this project is to identify key metabolic pathways that change with oral curcumin supplementation and to relate those changes with improvements in vascular function in MA/O adults with initial endothelial dysfunction. Metabolomic analysis of plasma samples at baseline also may produce unique molecular signatures that predict responsiveness (changes in vascular function) to curcumin supplementation among individuals. |
Institute: | Mayo Clinic |
Last Name: | Seals |
First Name: | Douglas |
Address: | Department of Integrative Physiology University of Colorado Boulder, CO 80309 |
Email: | seals@colorado.edu |
Phone: | 303-492-5305 |
Subject:
Subject ID: | SU000548 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Mammals |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | group | Time point |
---|---|---|---|
SA027611 | ms5533-29 | Old-Curcumin | Post |
SA027612 | ms5588-15 | Old-Curcumin | Post |
SA027613 | ms5588-22 | Old-Curcumin | Post |
SA027614 | ms5533-15 | Old-Curcumin | Post |
SA027615 | ms5533-18 | Old-Curcumin | Post |
SA027616 | ms5533-27 | Old-Curcumin | Post |
SA027617 | ms5533-20 | Old-Curcumin | Post |
SA027618 | ms5533-22 | Old-Curcumin | Post |
SA027619 | ms5588-27 | Old-Curcumin | Post |
SA027620 | ms5588-29 | Old-Curcumin | Post |
SA027621 | ms5533-3 | Old-Curcumin | Post |
SA027622 | ms5588-3 | Old-Curcumin | Post |
SA027623 | ms5588-25 | Old-Curcumin | Post |
SA027624 | ms5588-5 | Old-Curcumin | Post |
SA027625 | ms5533-10 | Old-Curcumin | Post |
SA027626 | ms5533-8 | Old-Curcumin | Post |
SA027627 | ms5533-26 | Old-Curcumin | Pre |
SA027628 | ms5588-14 | Old-Curcumin | Pre |
SA027629 | ms5588-4 | Old-Curcumin | Pre |
SA027630 | ms5533-28 | Old-Curcumin | Pre |
SA027631 | ms5533-19 | Old-Curcumin | Pre |
SA027632 | ms5533-9 | Old-Curcumin | Pre |
SA027633 | ms5588-24 | Old-Curcumin | Pre |
SA027634 | ms5533-7 | Old-Curcumin | Pre |
SA027635 | ms5588-26 | Old-Curcumin | Pre |
SA027636 | ms5533-2 | Old-Curcumin | Pre |
SA027637 | ms5533-14 | Old-Curcumin | Pre |
SA027638 | ms5588-28 | Old-Curcumin | Pre |
SA027639 | ms5533-21 | Old-Curcumin | Pre |
SA027640 | ms5588-2 | Old-Curcumin | Pre |
SA027641 | ms5533-17 | Old-Curcumin | Pre |
SA027642 | ms5588-21 | Old-Curcumin | Pre |
SA027643 | ms5588-18 | Old-Placebo | Post |
SA027644 | ms5588-10 | Old-Placebo | Post |
SA027645 | ms5588-13 | Old-Placebo | Post |
SA027646 | ms5588-20 | Old-Placebo | Post |
SA027647 | ms5588-8 | Old-Placebo | Post |
SA027648 | ms5533-32 | Old-Placebo | Post |
SA027649 | ms5533-34 | Old-Placebo | Post |
SA027650 | ms5588-32 | Old-Placebo | Post |
SA027651 | ms5588-34 | Old-Placebo | Post |
SA027652 | ms5533-25 | Old-Placebo | Post |
SA027653 | ms5533-13 | Old-Placebo | Post |
SA027654 | ms5588-36 | Old-Placebo | Post |
SA027655 | ms5533-5 | Old-Placebo | Post |
SA027656 | ms5533-36 | Old-Placebo | Post |
SA027657 | ms5533-4 | Old-Placebo | Pre |
SA027658 | ms5533-24 | Old-Placebo | Pre |
SA027659 | ms5588-19 | Old-Placebo | Pre |
SA027660 | ms5533-12 | Old-Placebo | Pre |
SA027661 | ms5588-35 | Old-Placebo | Pre |
SA027662 | ms5588-17 | Old-Placebo | Pre |
SA027663 | ms5533-31 | Old-Placebo | Pre |
SA027664 | ms5588-7 | Old-Placebo | Pre |
SA027665 | ms5588-31 | Old-Placebo | Pre |
SA027666 | ms5588-33 | Old-Placebo | Pre |
SA027667 | ms5533-33 | Old-Placebo | Pre |
SA027668 | ms5533-35 | Old-Placebo | Pre |
SA027669 | ms5588-9 | Old-Placebo | Pre |
SA027670 | ms5588-12 | Old-Placebo | Pre |
SA027671 | ms5588-37 | young | Baseline |
SA027672 | ms5588-30 | young | Baseline |
SA027673 | ms5588-1 | young | Baseline |
SA027674 | ms5533-23 | young | Baseline |
SA027675 | ms5533-16 | young | Baseline |
SA027676 | ms5533-11 | young | Baseline |
SA027677 | ms5533-6 | young | Baseline |
SA027678 | ms5533-30 | young | Baseline |
SA027679 | ms5533-37 | young | Baseline |
SA027680 | ms5588-16 | young | Baseline |
SA027681 | ms5588-11 | young | Baseline |
SA027682 | ms5588-6 | young | Baseline |
SA027683 | ms5533-1 | young | Baseline |
SA027684 | ms5588-23 | young | Baseline |
Showing results 1 to 74 of 74 |
Collection:
Collection ID: | CO000542 |
Collection Summary: | Healthy men & women aged 45-79 without clinical CVD, but with below normal baseline endothelial dysfunction (FMDBA < 7%). |
Sample Type: | Blood |
Treatment:
Treatment ID: | TR000562 |
Treatment Summary: | A 12-week randomized, double-blind, placebo controlled study will be conducted. After CTRC screening for inclusion/exclusion criteria, qualified subjects will be randomly assigned to 1 of 2 groups. The investigators involved in the acquisition and analysis of key outcomes will be blinded to the curcumin intake status of the subjects. With the assistance of dietary monitoring from the UC-Boulder CTRC bionutritionists, subjects will maintain their baseline diet with either unchanged (control) or enhanced curcumin intake delivered as capsules (Longvida®, Verdure Sciences): Group 1 = placebo (inert substances); Group 2 = curcumin (2000mg curcumin/day). Extensive published work has established that the curcumin dose of 2000 mg/day is well tolerated and safe. Sessions 1 & 2: Screening measurements. Session 3: Baseline measurements and blood draw. Sessions 4-8 (every other week to assess adherence and overall subject well-being): Body weight, BP, adherence, discuss any problems. Session 9: Identical to session 3 (stop intake of capsules after completion of post-testing). |
Sample Preparation:
Sampleprep ID: | SP000555 |
Sampleprep Summary: | Venous blood sampling. All blood samples are handled in a similar time frame and immediately spun to extract plasma and stored in our -80 freezer until ready for analysis. Ceramides concentrations in plasma. |
Combined analysis:
Analysis ID | AN000804 |
---|---|
Analysis type | MS |
Chromatography type | HILIC |
Chromatography system | Waters Acquity |
Column | AMT HALO HILIC 2 (150 x 4.6mm,2.7um) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | Thermo Quantiva QQQ |
Ion Mode | POSITIVE |
Units | uM |
Chromatography:
Chromatography ID: | CH000579 |
Instrument Name: | Waters Acquity |
Column Name: | AMT HALO HILIC 2 (150 x 4.6mm,2.7um) |
Chromatography Type: | HILIC |
MS:
MS ID: | MS000711 |
Analysis ID: | AN000804 |
Instrument Name: | Thermo Quantiva QQQ |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
Ion Mode: | POSITIVE |